National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings, 6880 [2022-02468]
Download as PDF
<![CDATA[
6880
Federal Register / Vol. 87, No. 25 / Monday, February 7, 2022 / Notices
created an immense public health,
social, and economic burden. Variants
of concern continue to emerge that have
increased transmissibility,
pathogenicity, or both and that reduce
the effectiveness of current therapeutics
and vaccines. Thus, there is a great need
for broadly protective therapeutics.
This technology relates to two
monoclonal antibodies targeting the
spike protein of SARS–CoV–2 that
between the two have picomolar activity
against wild-type SARS–CoV–2 and the
Alpha, Beta, Delta, and Omicron
variants of concern. Additionally, one of
the antibodies recognizes a highlyconserved epitope of the spike protein.
Treatment with either monoclonal
antibody before or after challenge with
SARS–CoV–2 reduced symptoms and
viral load in nasal turbinate and lung
tissue in the golden Syrian hamster
model. This monoclonal antibody
technology has great potential to treat
SARS–CoV–2 infections and may
provide protection against future
variants of concern.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404.
Potential Commercial Applications
• Treatment for SARS–CoV–2 infection
• Prophylaxis treatment to prevent or
reduce SARS–CoV–2 infection
• Diagnostic for SARS–CoV–2 infection
Competitive Advantages
• Broad and potent neutralization of
several variants of concern, including
Omicron
jspears on DSK121TN23PROD with NOTICES1
Development Stage
• In vivo data assessment (animal)
Inventors: Zhaochun Chen (NIAID);
Patrizia Farci (NIAID); Kamille West
(CC); Peng Zhang (NIAID); Paolo Lusso
(NIAID); Ulla Buchholz (NIAID);
Yumiko Matsuoka (NIAID).
Intellectual Property: HHS Reference
No. E–132–2021– U.S. Provisional
Application No. 63/296,380, filed
January 4, 2022.
Licensing Contact: To license this
technology, please contact Elizabeth
Pitts, Ph.D., 240–669–5299;
elizabeth.pitts@nih.gov, and reference
E–132–2021.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize this technology. For
collaboration opportunities, please
contact Elizabeth Pitts, Ph.D., 240–669–
5299; elizabeth.pitts@nih.gov.
VerDate Sep<11>2014
17:36 Feb 04, 2022
Jkt 256001
Dated: February 1, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2022–02466 Filed 2–4–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; NST 1 Member SEP.
Date: March 1, 2022.
Time: 9:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: William C. Benzing, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS, NIH, NSC, 6001 Executive
Boulevard, Suite 3204, MSC 9529, Rockville,
MD 20852, 301–496–0660, benzingw@
mail.nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; BRAIN Initiative: TeamResearch BRAIN Circuit Programs U19
Review.
Date: March 8–11, 2022.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Tatiana Pasternak, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH, NSC, 6001 Executive Boulevard,
Suite 3208, MSC 9529, Rockville, MD 20852,
301–496–9223, tatiana.pasternak@nih.gov.
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Biomarkers for the Lewy
Body Dementias.
Date: March 11, 2022.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Joel A. Saydoff, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH, NSC, 6001 Executive Boulevard,
Room 3205, MSC 9529, Rockville, MD 20852,
301–496–9223, joel.saydoff@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: February 1, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–02468 Filed 2–4–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Docket ID FEMA–2020–0016]
Plan of Action To Establish a National
Strategy for the Coordination of
National Multimodal Healthcare Supply
Chains To Respond to COVID–19;
Implemented Under the Voluntary
Agreement for the Manufacture and
Distribution of Critical Healthcare
Resources Necessary To Respond to a
Pandemic Under Section 708 of the
Defense Production Act
Federal Emergency
Management Agency, Department of
Homeland Security.
ACTION: Notice.
AGENCY:
The Federal Emergency
Management Agency (FEMA) is
publishing the text of one additional
Plan of Action under the Voluntary
Agreement for the Manufacture and
Distribution of Critical Healthcare
Resources Necessary to Respond to a
Pandemic: Plan of Action to Establish a
National Strategy for the Coordination
of National Multimodal Healthcare
Supply Chains to Respond to COVID–
19.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Robert Glenn, Office of Business,
E:\FR\FM\07FEN1.SGM
07FEN1
]]>Agencies
[Federal Register Volume 87, Number 25 (Monday, February 7, 2022)]
[Notices]
[Page 6880]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-02468]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice
of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; NST 1 Member SEP.
Date: March 1, 2022.
Time: 9:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
Contact Person: William C. Benzing, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural
Activities, NINDS, NIH, NSC, 6001 Executive Boulevard, Suite 3204,
MSC 9529, Rockville, MD 20852, 301-496-0660, [email protected].
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; BRAIN Initiative: Team-Research
BRAIN Circuit Programs U19 Review.
Date: March 8-11, 2022.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
Contact Person: Tatiana Pasternak, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural
Activities, NINDS/NIH, NSC, 6001 Executive Boulevard, Suite 3208,
MSC 9529, Rockville, MD 20852, 301-496-9223,
[email protected].
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; Biomarkers for the Lewy Body
Dementias.
Date: March 11, 2022.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
Contact Person: Joel A. Saydoff, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural
Activities, NINDS/NIH, NSC, 6001 Executive Boulevard, Room 3205, MSC
9529, Rockville, MD 20852, 301-496-9223, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.853,
Clinical Research Related to Neurological Disorders; 93.854,
Biological Basis Research in the Neurosciences, National Institutes
of Health, HHS)
Dated: February 1, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-02468 Filed 2-4-22; 8:45 am]
BILLING CODE 4140-01-P
